title: Pre-treatment levels of anti-HCV core IgM antibodies are closely associated with response to alpha interferon therapy in chronic hepatitis C patients.
abstract: OBJECTIVE
  To investigate the relationship between pre-treatment levels of anti-hepatitis C virus (HCV) immunoglobulin M (IgM) antibodies and the outcome of interferon therapy, and also the relationship with genotypes and quantitative viraemia.
  
  
  METHODS
  One hundred and four patients with biopsy-proven chronic hepatitis C without cirrhosis, consecutively enrolled in three general hospitals in Turin, Italy, and treated according to the same interferon schedule (3 MU of recombinant alpha-2b interferon three times a week for 6 months). Anti-HCV IgM were measured by a second-generation enzyme-linked immunoassay and results expressed as sample-cutoff ratio. In 30 patients, determination of viraemia by branched DNA (bDNA) and genotyping were performed and the correlation with anti-HCV IgM ratios was assessed.
  
  
  RESULTS
  According to univariate analysis, anti-HCV IgM ratios, age, serum gamma-glutamyltranspeptidase (gamma-GT) and ferritin levels were significantly associated with sustained response to therapy. A log-linear model, testing the effect of these variables on response to therapy, showed that anti-HCV IgM ratio was the only independently associated variable (P=0.00057). Anti-HCV IgM were associated with viraemia levels (r=0.57), but not with genotype distribution. Patients with anti-HCV IgM ratio less than 1 were sustained responders to the 'standard therapy' in 65% of cases. By contrast, among patients with a ratio greater than 3, sustained response was achieved in only one patient (3%), while 73% were non-responders; the majority of relapsers were found among patients with a ratio between 1 and 3.
  
  
  CONCLUSIONS
  Anti-HCV IgM antibodies provide an easily accessible and cheap serological marker of active viral replication, and are significantly related to the outcome of interferon therapy in patients with chronic hepatitis C.
authors.affiliation: Gastroenterology Division, Martini Nuovo Hospital, Turin, Italy.
authors.forename: M
authors.initials: M
authors.lastname: Tabone
authors.forename: P
authors.initials: P
authors.lastname: Secreto
authors.forename: C
authors.initials: C
authors.lastname: Marini
authors.forename: R
authors.initials: R
authors.lastname: Bonardi
authors.forename: M
authors.initials: M
authors.lastname: Boero
authors.forename: S
authors.initials: S
authors.lastname: Taraglio
authors.forename: E
authors.initials: E
authors.lastname: Ercole
authors.forename: F
authors.initials: F
authors.lastname: Sallio Bruno
authors.forename: A
authors.initials: A
authors.lastname: Pera
mesh_terms: D000328:Adult; D000367:Age Factors; D001706:Biopsy; D004797:Enzyme-Linked Immunosorbent Assay; D005260:Female; D006526:Hepatitis C / Q000097:blood / Q000188:drug therapy* / Q000276:immunology*; D018937:Hepatitis C Antibodies / Q000097:blood*; D006801:Humans; D007075:Immunoglobulin M / Q000097:blood*; D016898:Interferon-alpha / Q000627:therapeutic use*; D008297:Male; D008875:Middle Aged; D011379:Prognosis; D012698:Serologic Tests; D014779:Virus Replication / Q000187:drug effects
chemical_list: D018937:Hepatitis C Antibodies; D007075:Immunoglobulin M; D016898:Interferon-alpha